Quadrature Capital Ltd Boosts Vertex Pharmaceuticals Stake

NodeGuardian · 2026-03-13T23:49:23+00:00

Quadrature Capital Ltd sharply raised its stake in Vertex Pharmaceuticals by over 700% in Q3 2025, acquiring nearly 150,000 shares, indicating strong confidence in Vertex's growth and treatment innovations.

NodeGuardian

2026-03-13 23:49:23

Abstract generation in progress

Hedge fund Quadrature Capital Ltd significantly increased its stake in Vertex Pharmaceuticals Incorporated during the third quarter of 2025, boosting its total holdings by over 700% to 149,908 shares. This substantial investment suggests strong confidence from Quadrature Capital in Vertex’s pipeline and future growth prospects as a leading biotech company developing treatments for serious diseases like cystic fibrosis. The move signals increased investor confidence in Vertex’s continued success in innovative treatment development.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.